Pneumococcal

Cost considerations for the rollout of new pneumococcal vaccines are discussed by a panel of medical experts.

Dr Schaffner underscores the significance of multidisciplinary teams in the effort to optimize vaccination rates for pneumococcal disease.

Christina Madison, PharmD, FCCP, AAHIVP, discusses disparities in patient populations directly influencing limited access to appropriate treatment and preventative care.

The significance of engaging patients and providing key educational points regarding pneumococcal vaccines is highlighted.

Antibiotic prescribing at hospital discharge is a component of pharmacist-led antimicrobial stewardship programs that is often overlooked.

Medical experts discuss clinical, social, and economic obstacles limiting pneumococcal vaccination efforts.

The panelists discuss the evolution of the pneumococcal vaccine landscape.

Study shows maternal vaccination with Pfizer’s hexavalent capsular polysaccharide conjugate vaccine may protect infants against Group B Streptococcus.

If approved, the V116 vaccine would be the first pneumococcal conjugate vaccine specifically designed for adults.

Secondary pneumococcal vaccine schedules are explored by Drs Schaffner, Bridgeman, and Madison.

Dr. Bridgeman highlights approved pneumococcal vaccines and their indications.

Mary Bridgeman, PharmD, BCPS, BCGP, FASCP, drives a discussion around preventative measures to limit the spread of pneumococcal infection.

William Schaffner, MD, and Christina Madison, PharmD, FCCP, AAHIVP provide an overview of the identification and differential diagnosis of pneumococcal pneumonia.

High-risk patient populations for pneumococcal pneumonia are discussed by Christina Madison, PharmD, FCCP, AAHIVP.

Key opinion leaders discuss factors leading to the development of novel pneumococcal vaccines.

Despite injection site adverse effects, the overall benefit-risk balance for pneumococcal vaccination remains favorable.

COVID-19 is helping to shape current pharmacy practice, including increased vaccinations, access to care, and better interactions with patients.

Medical experts provide an overview of the signs and symptoms of pneumococcal infections.

As the COVID-19 Public Health Emergency and PREP Act Expansions end, the ability of technicians to immunize patients in the future remains unclear.

Immunocompromised status still appears to be one of the highest independent risk factors for pneumococcal pneumonia in middle-aged and older adults.

Pharmacists who immunize must ensure their knowledge about routine vaccinations for adults and children is up-to-date by reviewing the changes to the immunization schedule each year.

Myths, fears, distrust, and misinformation on immunizations can keep patients from benefiting from their protective effects.

Treatment for community-acquired pneumococcal disease is dependent on patient-specific factors, whereas prevention with vaccinations is dependent on age and comorbidities.

As the summer months approach, pharmacists can offer many services to ensure patients remain safe and healthy during their travels.

Study findings suggest surveillance and prevention programs are needed for this common and deadly complication of hospitalization.